Title:
膀胱癌のマーカーとしてのクロモグラニンＡ
Document Type and Number:
Japanese Patent JP6831852
Kind Code:
B2
Abstract:
The present invention relates to the use of Chromogranin A (CgA) as a marker (particularly a prognostic marker) for bladder cancer, particularly non-neuroendocrine bladder cancer and preferably urothelial carcinoma. In particular, CgA can be used as a marker in an in vitro assay for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma). The invention further pertains to a method for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma) in a subject, comprising the step of determining the level of CgA and optionally MMP7 in a sample of a bodily fluid of said subject.
Inventors:
Jardin Watertre Benedict
Bourgoin Nicolas
Salvastibor
Bourgoin Nicolas
Salvastibor
Application Number:
JP2018547478A
Publication Date:
February 17, 2021
Filing Date:
March 07, 2017
Export Citation:
Assignee:
Cezanne Society Axion Simplicity
International Classes:
G01N33/68; G01N33/574
Domestic Patent References:
| JP2008507558A |
Foreign References:
| WO2015158701A1 |
Other References:
K A Iczkowski et al.,Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense γ-enolase expression,HISTOPATHOLOGY,1999年,Vol.35, No.2,pp.150-156
TROPEA F. et al.,Evaluation of Chromogranin A Expression in Patients with Non-Neuroendocrine Tumours,Clinical Drug Investigation,2006年,vol.26,pp.715-722
TSAO Kuo-Chien, WU James T,Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas,Clinica Chimica Acta,2001年,Vol.313, No.1-2,pp.21-29
MOLINA Rafael et al.,Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.,Tumor Biology,2011年,Vol. 32, No. 1,pp.13-22
TROPEA F. et al.,Evaluation of Chromogranin A Expression in Patients with Non-Neuroendocrine Tumours,Clinical Drug Investigation,2006年,vol.26,pp.715-722
TSAO Kuo-Chien, WU James T,Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas,Clinica Chimica Acta,2001年,Vol.313, No.1-2,pp.21-29
MOLINA Rafael et al.,Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.,Tumor Biology,2011年,Vol. 32, No. 1,pp.13-22
Attorney, Agent or Firm:
Patent Service Corporation Patent Office Sykes